Clinical trials: Randomized Controlled Trial, Human Study
Chikungunya, Chikungunya Fever
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
This is a Phase I, randomized, single-blind, placebo-controlled, study of four separate dose cohorts, with a 42-day interval between each vaccine dose, of a novel Chikungunya Peptide Immunotherapy Vaccine in Healthy Adults (18-60…
- Conditions
- Chikungunya, Chikungunya Fever, Chikungunya Virus Infection, Chikungunya Virus Infections
- Trial name
- NCT07394426
- Testing
- PepGNP-ChikV
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
Hypertension
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
- Trial name
- NCT00422461
- Testing
- PF-00489791
- Where
- 20 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pfizer
Hepatitis B, Chronic Hepatitis B
Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
This exploratory study is designed to determine the early viral kinetic profile during treatment with telbivudine or entecavir at multiple time points over 12 weeks.
- Trial name
- NCT00412529
- Testing
- Entecavir, Telbivudine
- Where
- 8 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Knee
Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis
Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).
- Trial name
- NCT05100225
- Testing
- PTP-001
- Where
- 14 sites in Australia, Canada and 1 more
- Volunteers
- 210 people
- Sponsor
- Bioventus LLC
Healthy
Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults
This is the first study of MTP-131 (Bendavia™) in humans. The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single intravenous infusion doses of MTP-131.
- Trial name
- NCT01115920
- Testing
- MTP-131 (Bendavia™)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mighty Therapeutics, Inc.
Chronic Hepatitis b
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b
This is an open label, randomized, multi-center, comparative study. Subjects will be screened prior to study entry to establish eligibility.
- Trial name
- NCT04157699
- Testing
- TDF tablet, QL-007
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Influenza
Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults
The purpose of this study is to evaluate the safety and immune response of two-doses of GSK Biologicals' candidate influenza vaccine GSK 1557484A with or without adjuvant in adults.
- Trial name
- NCT00510874
- Testing
- Pumarix™, Pandemrix ™
- Where
- 10 sites in United States, Canada
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Psoriasis
Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis
The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.
- Trial name
- SPIRIT (NCT00244842)
- Testing
- voclosporin
- Where
- 31 sites in Canada
- Volunteers
- 451 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis…
- Trial name
- STARSCAPE (NCT04552899)
- Testing
- PRM-151 (Zinpentraxin Alfa)
- Where
- 360 sites in United States, Argentina and 33 more
- Volunteers
- 665 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone…
- Trial name
- NCT02258464
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Background hormonal therapy
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Hepatitis C
Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
The purpose of this research trial is to find out whether NOV-205 is well tolerated compared to placebo (salt water) in people with hepatitis C.
- Trial name
- NCT00372983
- Testing
- NOV-205
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.
Chronic Hepatitis b
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy
This is an open label, randomized, multi-center, comparative study. Subjects will be screened prior to study entry to establish eligibility.
- Trial name
- NCT04157257
- Testing
- TDF tablet, Entecavir Tablet, QL-007
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Influenza, Influenza A
Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI
The goal of this prospective, digital randomized controlled trial is to evaluate the effectiveness of a predictive ILI detection algorithm and associated alerts during influenza season for adults living in the contigent United…
- Conditions
- Influenza, Influenza A, Influenza B, COVID-19
- Trial name
- NCT06229444
- Testing
- ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content
- Where
- United States
- Volunteers
- 17,043 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Influenza
Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)
Clinical Trial in Two parts: Part 1: Phase I, Open-Label, Single-Center Study to Evaluate the Safety of an adjuvanted Influenza Vaccine When Administered to Elderly Subjects.
- Trial name
- NCT00310648
- Testing
- Influenza vaccine
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Novartis
Rheumatoid Arthritis
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid…
- Trial name
- NCT00361335
- Testing
- Golimumab, Methotrexate
- Where
- 72 sites in United States, Argentina and 13 more
- Volunteers
- 643 people
- Sponsor
- Centocor, Inc.
Papilloma Viral Infection
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Primary objective To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
- Trial name
- NCT02114385
- Testing
- V503, GARDASIL
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or…
- Trial name
- NCT07003074
- Testing
- TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
- Where
- 25 sites in China
- Volunteers
- 642 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Healthy Subjects
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
This is first in human (FIH), double-blind, sponsor open, placebo-control trial to examine the safety, tolerability, pharmacokinetics and pharmacodynamics following a single ascending doses of PF-06648671 in healthy subjects.
- Trial name
- NCT02316756
- Testing
- PF-06648671
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Heart Failure
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.
- Trial name
- NCT03388593
- Testing
- rhNRG-1
- Where
- 65 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Root Canal Treatment, Post Operative Pain
A First in Human Study to Compare Feasibility of Inertial Cavitation Irrigation to SNI in Root Canal Treatment.
The study design is a single-center 2-arm randomized controlled clinical trial. 10 subjects (teeth) requiring a root canal treatment will be enrolled in 2 groups (5 in each group).
- Trial name
- NCT05374434
- Testing
- Conventional irrigation, Inertial cavitation
- Where
- Turkey (Türkiye)
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Lumendo AG